时珍国医国药2026，Vol.37Issue(3)：461-468,8.DOI:10.70976/j.1008-0805.SZGYGY-2026-0309
鱼酱排毒合剂调控HIF-1信号通路改善慢性鼻窦炎氧化应激的作用机制
Study on the mechanism of YuJiang Paidu Decoction(鱼酱排毒合剂)in regulating the HIF-1 signaling pathway to ameliorate oxidative stress in chronic rhinosinusitis
摘要
Abstract
Objective To investigate the mechanism of YuJiang Paidu Decoction(鱼酱排毒合剂,YJPDD)in ameliorating oxidative stress in chronic rhinosinusitis(CRS)by regulating the HIF-1 signaling pathway.Methods A CRS mouse model was established using OVA+AP nasal drops.Mice were divided into a control group(NC),a model control(MC),a positive control dexamethasone group(Dexa),a low-dose YJPDD group(YJ-L),and a high-dose YJPDD group(YJ-H).Human nasal epithelial cells(HNEpCs)were treated with 0.4 mmol/L tert-butyl hydroperoxide(TBHP)to to construct a cell model.Cell viability was assessed via CCK-8 assay,while mouse nasal cavities was observed using hematoxylin-eosin(HE)staining.Western blot(WB)and qPCR were performed to evaluate inflammatory factors,HIF-1 pathway pathway-related proteins and gene expression,and oxidative stress indicators were assessed.Results Compared with the MC group,the Dexa,YJ-H,and YJ-L groups showed improved pathological structure of the nasal cavity,reduced inflammatory cell infiltration,and suppressed expression of inflammatory factors IL-4,IL-5,and IL-13,and alleviated oxidative stress,with the superior effect of the YJ-H group compare to the YJ-L group.YJPDD demonstrating dose-dependent reduc-tions in intracellular ROS,GSSG/GSH,and MDA levels,alongside enhanced SOD and CAT activity,and inhibited the protein expres-sion of HIF-1α,VEGF,and VEGFR2.Conclusion YJPDD ameliorates inflammatory response and oxidative stress in CRS by regulat-ing the HIF-1 signaling pathway,thereby inhibiting the pathological progression of the disease.关键词
鱼酱排毒合剂/氧化应激/慢性鼻窦炎/HIF-1信号通路Key words
YuJiang Paidu Decoction(鱼酱排毒合剂)/Oxidative stress/Chronic rhinosinusitis/HIF-1 signaling pathway分类
医药卫生引用本文复制引用
王亚萍,李玲珑,熊娟,舒福,林瑛,幸雪瑶,张锋..鱼酱排毒合剂调控HIF-1信号通路改善慢性鼻窦炎氧化应激的作用机制[J].时珍国医国药,2026,37(3):461-468,8.基金项目
重庆市科卫联合中医药医学科研项目(2023MSXM175) （2023MSXM175）
重庆市中医药创新团队项目(渝中医[2022]33号) （渝中医[2022]33号）
